Success stories

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients

Over the past decade, the treatment of Chronic Myeloid Leukemia (CML) has been revolutionized by the introduction of tyrosine kinase inhibitors (TKI). For patients achieving a deep molecular response, stopping TKI treatment – treatment-free remission (TFR) – becomes a possibility. This study, conducted by RCTs, aimed to develop predictive models for the success or failure of treatment-free remission based on clinical data coupled with French healthcare database system (Système National des Données de Santé (SNDS)). This indirect linkage (i.e., using common variables between the two databases) was carried out by RCTs using a deterministic matching algorithm developed by the RCTs secondary data team. For prediction, logistic regression models and machine learning algorithms were tested. This study provides an example of developing predictive models/decision support tools, developed from patients’ clinical data enriched with SNDS data.

N° T40786692021052 (https://www.health-data-hub.fr/projets/real-life-treatment-patterns-and-burden-illness-among-patients-chronic-myeloid-leukemia-cml)

Data Controller: Novartis

Data Processor: RCTs

Scientific Committee: Franck-Emmanuel Nicolini

Risk Factors TFR CP-CML Risk Factors TFR CP-CML 

 

Risk Factors TFR CP-CML

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Publication Bias in Drug Safety: RCTs Study on Bisphosphonates
Publications - Success stories - Rhumatologie - Facultatif

Publication Bias in Drug Safety: RCTs Study on Bisphosphonates

regenlife
Publications - Success stories - Neurologie - Facultatif

Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases

Long-Term TKI Treatment Patterns
Success stories - Oncologie - Facultatif

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life”